About Us

Vaccination plays a crucial role in preventing and controlling these diseases, leading to a substantial annual increase in global demandfor vaccines.

From this perspective, OGV Biotec LLC established in 2024, as a private German Omani joint venture, with the aim of creating a state-of-the-art facility for producing various veterinary vaccines using the latest technological equipment

1.Providing veterinary vaccines that meet the highest international quality and control standards, including ISO, Good Manufacturing Practices (GMP), and US Food and Drug Administration (FDA) regulations.

2.Collaborating with scientific and research institutions to build strategic partnerships to provide innovative and effective vaccine solutions against diseases, serving the community using the latest European scientific technologies.

3.Maintaining food and drug security and public health by protecting animal health.

4.Applying the highest sustainability standards and adopting environmentally friendly manufacturing practices.

5.Providing ongoing technical and scientific support to veterinarians and animal breeders for disease prevention and the maintenance of a sustainable livestock population.

Providing innovative veterinary vaccine solutions that contribute to protecting animal health, maintaining sustainable livestock resources, and promoting human health..

1.Responsibility towards society and the environment.

2.Quality and excellence in scientific research and innovation.

3.Commitment to ensuring the highest standards of safety and security in production.

4.Adherence to the regulatory guidelines of animal health organizations.

5.Employing the best professional talent and working as a unified team.

6.Transparency and integrity in all dealings.

OGV Biotech is committed to achieving production management using highly advanced, fully automated systems to ensure comprehensive environmental cleanliness and sterility.

Quality control is the most important aspect of OGV Biotech's production process. These controls are subject to the European Pharmacopoeia and Good Manufacturing Practices (cGMP) regulations, in addition to compliance with ISO and FDA standards.

These include the analysis of all incoming raw materials, in-process control procedures, final inspections before product placement on the market, and specific microbiological control procedures to contain any bacterial load. Specialists also test the potency of all manufactured products to verify their safety and efficacy.Production is carried out in Class 100 sterile environments, and all production areas are equipped with laminar flowsystems. These systems are essential to meet the microbiological and quality requirements of production environments and processe.